Microglia are implicated in all stages of multiple sclerosis (MS). Microglia alterations are
detected by positron emission tomography in people living with MS prior to the formation of …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …

Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …

BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the
progressive loss of axonal myelin in several areas of the central nervous system (CNS) that …

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are
immunotherapies that target various B cell–related proteins. Most of these treatments have …

Multiple sclerosis (MS) is a chronic, autoimmune, and neurodegenerative disease of the
central nervous system (CNS) that affects myelin. The etiology of MS is unclear, although a …

Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate—GA) are being
examined, primarily in neurological conditions involving cognitive decline. GA is a well …

Abstract Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city
of Wuhan and has quickly become a global pandemic. The disease is caused by the severe …